Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (CSE: MBIO ) 0.0250 UNCHANGED Streaming Delayed Price Updated: 10:06 AM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.0250 Bid (Size) 0.0200 (124,000) Ask (Size) 0.0300 (40,000) Prev. Close 0.0250 Today's Range 0.0250 - 0.0250 52wk Range 0.0150 - 0.0800 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials August 19, 2024 Via ACCESSWIRE MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory August 01, 2024 Via ACCESSWIRE Performance YTD +25.00% +25.00% 1 Month -16.67% -16.67% 3 Month -28.57% -28.57% 6 Month -50.00% -50.00% 1 Year -28.57% -28.57% More News Read More Mindbio Therapeutics CEO Issues Letter To Shareholders July 08, 2024 Via ACCESSWIRE MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials June 20, 2024 Via ACCESSWIRE MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial June 12, 2024 Via ACCESSWIRE MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials April 30, 2024 Via ACCESSWIRE MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry April 22, 2024 Via ACCESSWIRE Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders May 14, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders May 14, 2024 Via ACCESSWIRE MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month May 02, 2024 Via ACCESSWIRE MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3 May 01, 2024 Via ACCESSWIRE LSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issues April 30, 2024 Via Benzinga Lender Requests to Convert Loan to MindBio Shares April 16, 2024 Via ACCESSWIRE MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder March 20, 2024 Via ACCESSWIRE MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder March 04, 2024 Via ACCESSWIRE MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial February 25, 2024 Via ACCESSWIRE MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial February 13, 2024 Via ACCESSWIRE MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients January 29, 2024 Via ACCESSWIRE MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials December 20, 2023 Via ACCESSWIRE MindBio Therapeutics Team Members Honoured with Industry Leading Awards November 21, 2023 Via ACCESSWIRE MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients October 31, 2023 Via ACCESSWIRE MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients October 28, 2023 Via ACCESSWIRE Mindbio Therapeutics Nominated for Company of the Year in Industry Awards October 26, 2023 Via ACCESSWIRE MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001 October 24, 2023 Via ACCESSWIRE Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials October 05, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.